Banner Image for Directory

Directory



Lim Wan-Teck Darren

Associate Professor

Email

Education Qualifications: MBBS, MRCP (UK)

Dr Darren Lim is a Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore. His clinical interests are in lung, thyroid, nasopharygeal and head and neck cancers. 

 

Professional Appointments and Committee Memberships:

  • Associate Professor, Duke-NUS Medical School Singapore
  • Director of Research, Department of Medical Oncology, National Cancer Centre Singapore
  • Senior PI, Institute of Molecular and Cell Biology, A*STAR
  • Member, International Association for the Study of Lung Cancer
  • Member, Singapore Society of Oncology
  • Fellow, Academy of Medicine Singapore

Awards:

  • Outstanding Clinician Researcher Award (Special Mention), GCEO Excellence Awards, SingHealth Excellence Awards 2013
  • Clinician Scientist Award (INV Category) 2012 and 2017
  • Health Manpower Development Plan (HMDP) Award, SingHealth, 2004-2005
  • Excellent Service Award 2009, Gold Award
  • Excellent Service Award 2008, Silver Award

Research Interests: Early phase clinical trials with biological correlates, and specific focus on circulating biomarkers.

Selected Publications:

Toh CK, Ong WS, Tan DS, Ng QS, Kanesvaran R, Fong KW, Ang MK, Tan EH, Lim WT. Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade. Ann Acad Med Singapore. 2017 Sep;46(9):333-338

Ma BB, Lim WT, Goh BC, et al. Antitumor activity of nivolumab and biomarkers in recurrent and metastatic nasopharyngeal carcinoma: An international multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742, NCT02339558).  J Clin Oncol. 2018 May 10;36(14):1412-1418. 

Tan EH, Lim WT, Ahn MJ, Ng QS, Ahn JS, Shao-Weng Tan D, Sun JM, Han M, Payumo FC, McKee K, Yin W, Credi M, Agarwal S, Jac J, Park K.  Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. Clin Pharmacol Drug Dev 2018 Jun;7(5):532-542. doi: 10.1002/cpdd.427.

PT Tan, MI Abdul Aziz, F Pearce, WT Lim, MC Tan, DB Wu, K Ng. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer in Singapore.  BMC Cancer. 2018 Mar; 18:352. https://doi.org/10.1186/s12885-018-4223-y

CK Toh, WS Ong, WT Lim, DSW Tan, QS Ng, R Kanesvaran, WJ Seow, MK Ang, EH Tan. A decade of never-smokers among lung cancer patients - rising trend and improved survival.  Clin Lung Cancer. 2018 Sep;19(5):e539-e550. pii: S1525-7304(18)30055-X.  

Y Simoni, E Becht, M Fehlings, CY Loh, SL Koo, KWW Teng, JPS Yeong, R Nahar, T Zhang, H Kared, K Duan, N Ang, M Podinger, YY Lee, A Larbi, AJ Khng, E Tan, C Fu, ¬R Mathew,¬ M Teo, WT Lim, CK Toh, BH Ong, T Koh, A Hillmer, A Takano, TKH Lim, EH Tan, WW Zhai, DSW Tan, IB Tan, EW Newell.  Bystander CD8+ T cells are abundant and phenotypically distinct in human tumor infiltrates. Nature 2018 May; 557 (7706): 575-579.

Lim SB, Tan SJ, Lim WT, Lim CT. A merged lung cancer transcriptome dataset for clinical predictive modeling. Sci Data. 2018 Jul 24;5:180136.  Doi: 10.1038/sdata.2018.136

Tan WL, Ng QS, Lim C, Tan EH, Toh CK, Ang MK, Kanesvaran R, Jain A, Tan DSW, Lim DW. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer. 2018 Dec 3;18(1):1198. doi: 10.1186/s12885-018-5110-2

GGY Lai, TH Lim, J Lim, PJR Liew, XL Kwang, R Nahar, ZW Aung, A Takano, YY Lee, DPX Lau, GS Tan, SH Tan, WL Tan, MK Ang, CK Toh, BS Tan, A Devanand, CW Too, A Gogna, BH Ong, TPT Koh, R Kanesvaran, QS Ng, A Jain, T Rajasekaran, J Yuan, TKH Lim, AST Lim, AM Hillmer, WT Lim, NG Iyer, WL Tam, W Zhai, EH Tan, DSW Tan. Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor mutant non-small cell lung cancer. J Clin Oncol. 2019 Jan 18.00177.

CT Lim, SB Lim, M Chua, J Yeong, SJ Tan, WT Lim. Pan-cancer analysis connects tumor matrisome to immune response. npj Precision Oncology 2019 May 22:3:15.

SB Lim, T Yeo, WD Lee, AA Bhagat, SJ Tan, DSW Tan, WT Lim, CT Lim. Addressing Cellular Heterogeneity in Tumor and Circulation for Refined Prognostication. PNAS 2019 (accepted)

V Teneggi, V Novotny-Diermayr, L Lee, M Yasin, P Yeo, KK Ethirajulu, S Gan, S Blanchard, R Nellore, D Umrani, R Gomeni, DWT Lim, G Li, Q Lu, Y Cao, A Matter. First-in-Human, Healthy Volunteers,Integrated Protocol of ETC-206, an Oral MNK 1/2 Kinase Inhibitor Oncology Drug. Clinical and Translational Science 2019 (in press)

SB Lim, SJ Tan, DWT Lim, CT Lim. Compendiums of cancer transcriptome for machine learning applications. Sci Data 2019 (accepted) 

YS Yap, MC Leong, YW Chua, KWJ Loh, GE Lee, EH Lim, R Dent , RCH Ng, JH Lim,  G Singh, A Tan, G Guan, A Wu, YF Lee, AA Bhagat, DWT Lim. Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform. PLOSOne (in press)